PRIVA-MOXIFLOXACIN TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)

متاح من:

PHARMAPAR INC

ATC رمز:

J01MA14

INN (الاسم الدولي):

MOXIFLOXACIN

جرعة:

400MG

الشكل الصيدلاني:

TABLET

تركيب:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

100

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

QUINOLONES

ملخص المنتج:

Active ingredient group (AIG) number: 0142242001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2019-08-29

خصائص المنتج

_Priva-MOXIFLOXACIN _
_ _
_Page 1 of 60 _
PRODUCT MONOGRAPH
PR PRIVA-MOXIFLOXACIN
Moxifloxacin Tablets
(as moxifloxacin hydrochloride)
400 mg
Antibacterial Agent
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
October 16, 2015
Mont-Royal
Qc, H4T 1E2
CONTROL #: 187798
_Priva-MOXIFLOXACIN _
_ _
_Page 2 of 60 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................................................
5
ADVERSE REACTIONS
...........................................................................................................................
12
DRUG INTERACTIONS
............................................................................................................................
15
DOSAGE AND ADMINISTRATION
........................................................................................................
17
OVERDOSAGE
..........................................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
19
STORAGE AND STABILITY
....................................................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............